Blood Test Starts the Process
Getting started with The Woodlands Institute for Health & Wellness is easy. One diagnostic tool used during treatment is a blood test. Though we can learn from your symptoms, it is still important to have routine blood work done as it can also be insightful.
Depending on the program in which you are enrolled, the labs ordered will vary. You will receive a lab order at your initial appointment that you will take to a lab facility the following morning while fasting. Once your labs are received and reviewed by the medical staff, they will be reported to you, along with recommendations, by email (or phone, if you prefer). You will also be given a copy of your labs for your own records.
To get started, contact us to make your initial appointment with The Woodlands Institute for Health and Wellness.
Other Speciality Testing available at The Woodlands Institute for Health and Wellness:
Food Sensitivities are tested using US Biotek Food sensitivity panels. The testing options range from 96-208 general foods and test for IgG response only or you can selectet IgG with IgA to identify even more sensitivities.
Cell Sciences testing is used to detect genetic variations in the methylation pathway. Thier MethylDetox Profile includes genetic markers involved in methylation and homocysteine metabolism provided in a detailed lab report.
The DNA ConneXions® Lyme test panel identifies four different Borrelia species and ten of its common co-infectors. A positive PCR result indicates the presence of targeted microbes, while a negative result does not prove you don’t have Lyme disease.
Doctor’s Data comprehensive stool analysis is the starting point for pinpointing the causes of gastrointestinal symptoms and chronic conditions, and measures key markers of digestive and absorptive function and inflammation, all to guide targeted treatment selection.
Doctor’s Data Heavy Metal Test evaluates exposure to potentially toxic elements and wasting of nutrient elements. Exposure to toxic elements can result in significant retention in the body that can be associated with a vast array of adverse health effects and chronic disease.
Genova Metabolomix+ is a unique combination of nutritional tests that provides an analysis of key nutritional biomarkers. This panel is a way to assess the functional need for antioxidants, B-vitamins, minerals, digestive support, fatty acids, and amino acids. Insights gained from the Metabolomix+ nutritional test allows clinicians to target nutritional therapies to meet the precise needs of their patients.
Genova NutrEval Plasma is both a blood and urine test that evaluates over 125 biomarkers and assesses the body’s functional need for 40 antioxidants, vitamins, minerals, essential fatty acids, amino acids, digestive support, and other select nutrients. Personalized recommendations for nutrients are determined by using an algorithm based on the patient’s test findings.
GX Sciences is an advanced comprehensive Nutrigenomic, Pharmacogenomic test with a customized reporting platform that allows your medical provider to validate your specific nutritional needs, laboratory recommendations, lifestyle recommendations, and health precautions based on your individual DNA findings.
Health Diagnostics and Research Institute Nagalase test measures the activity of an enzyme α-N-acetylgalactosaminidase (nagalase) in blood. Nagalase is an extracellular matrix-degrading enzyme that is secreted by cancerous cells in the process of tumor invasion. It is also an intrinsic component of the envelope protein of various virions, such as HIV and the influenza virus. Thus, it is also secreted from virus-infected cells. The great sensitivity of the test may help your medical provider in obtaining a better understanding of the therapy and to fine-tune the treatment.
SpectraCell’s Micronutrient test measures 31 vitamins, minerals, amino/fatty acids, antioxidants, and metabolites – and how they affect cellular function in a person. Correlating micronutrient deficiencies not only slows aging and degenerative disease progression, it can also prevent as well as repair cellular dysfunction, and by extension, disease.
The Vibrant Wellness Tickborne Diseases panel is the first of its kind to be run on a silicon micro-array platform, providing the highest level of specificity and sensitivity in the industry for detecting tickborne diseases. Patients often present with a range of non-specific symptoms that may be Lyme, or other conditions that have symptom overlap. Patients with diagnosed Lyme may also experience resurgence of symptoms, which might suggest co-infections. Co-infections are complex and should be included in an initial screen of Lyme and related illnesses. Vibrant has the most comprehensive antibody (indirect) and DNA (direct) test for detection of Lyme and co-infections that, in most cases, can assist your medical provider in assessing these situations and lead to the correct diagnosis.
ZRT Saliva testing is a non-invasive collection method where you can collect your saliva in plastic tubes in order to measure hormones like cortisol, estrogens, progesterone, and androgens. Saliva testing measures the amount of hormone available to target tissues – the bioavailable amount. For this reason, saliva testing better relates to specific symptoms of excess or deficiency, and is a good option for monitoring hormone therapy.
RGCC Immune-Frame is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off. The results of Immune-Frame can be used to analyze the status of a patient’s immune system, and to provide ongoing information about their health status. This information can be used by your medical provider to advise on potential health risks a patient may face, and how these can be minimized.
RGCC Metastat is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location. We analyze a sample to identify and measure circulating tumour cells (CTCs). Metastat RGCC is suitable for all patients who have received a confirmed cancer diagnosis. The test can accurately detect the development of secondary cancers or tumours and improve personalized cancer treatments.
RGCC Onconomics Plus provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. A sample of blood or tissue is analyzed to test how effective specific therapies and treatments are at suppressing cancer. Together, the results of the extensive tests provide your medical provider with a comprehensive breakdown of the most suitable and successful treatments for cancer. The results can be used to design personalized and targeted cancer therapies with the highest chances of success.
RGCC Oncotrail provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer. The blood is analyzed to identify the presence and concentration of CTC and their immunophenotype. Oncotrail RGCC isn’t used as a primary diagnostic test to confirm a cancer diagnosis, but provides essential information on the effectiveness of current cancer treatments. Follow-up tests can also be used to monitor a patient’s health and assess the risk of relapse.
RGCC Oncotrace is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis. The blood is analyzed to identify the presence and concentration of circulating tumour cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their concentration and specific type (immunophenotype). The results of the test enable clinicians to identify the origin of a tumour where this is unknown and to provide information on the development of cancer and the prognosis.
RGCC Oncocount detects the presence of circulating tumour cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning. The test is designed as a follow-up test for patients who have cancer and are worried about the disease returning. Clinicians can use the Oncocount RGCC test to assess how effective cancer treatment is and the likelihood of cancer returning (relapse).
RGCC PaldiSpot test detects the presence of Borrelia, Babesia and Bartonella genospecies in a DNA sample. Used in combination with our PrimeSpot test, the PaldiSpot test provides critical information for patients with Lyme Disease and chronic fatigue syndrome. The results can help your medical provider develop effective personalized treatment and therapies. The PaldiSpot test is clinically validated and highly accurate. It is suitable for adults aged 18 and over.
RGCC PrimeSpot test detects and quantifies specific viruses and Lyme Disease-associated species in a blood sample. When used in combination with the PaldiSpot test, the PrimeSpot test provides critical information that can inform the development of personalized treatments and therapies for Lyme Disease, chronic fatigue syndrome and other medical conditions. The PrimeSpot test is clinically validated and highly accurate. It is suitable for adults aged 18 and over.